Praxis Medical Insights

Introduction to Buspirone Augmentation

The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology explicitly states that social anxiety disorder symptoms cannot be explained by autism spectrum disorder, and patients with developmental disorders (including autism) are specifically excluded from their social anxiety disorder treatment guidelines 1, 2
The American College of Physicians rates the evidence for buspirone augmentation as low quality, meaning substantial uncertainty exists about the magnitude of benefit 4, 5

The STAR*D trial found no difference in efficacy when augmenting citalopram (an SSRI similar to sertraline) with buspirone compared to bupropion or cognitive therapy for depression/anxiety 3, 4
Buspirone had significantly fewer discontinuations due to adverse events (12.5%) compared to other augmentation strategies (20.6%; P < 0.001), making it safer but not more effective 3, 4, 5
Cognitive therapy augmentation showed similar efficacy with potentially fewer adverse events and should be discussed as an alternative 4

If the patient has autism, reassess the diagnosis to determine whether social anxiety symptoms are better explained by autism spectrum disorder itself rather than true social anxiety disorder 1, 2
If symptoms are autism-related social difficulties, consider buspirone monotherapy as it has shown promise for anxiety in autism with excellent tolerability 4
If true comorbid social anxiety disorder exists, recognize you are treating an off-guideline population; buspirone augmentation offers no efficacy advantage but has better tolerability than alternatives 3, 4

Start buspirone at 5 mg twice daily and titrate gradually to 10-30 mg twice daily (maximum 20 mg three times daily) 4, 5
Allow 2-4 weeks for full therapeutic effect—unlike benzodiazepines, buspirone is not immediately effective 4, 5
Monitor for serotonin syndrome in the first 24-48 hours after initiation or dose changes (mental status changes, neuromuscular hyperactivity, autonomic hyperactivity), though risk is theoretical 4

Buspirone has no addiction potential, tolerance, or cognitive impairment unlike benzodiazepines, making it safer for long-term use 4, 5
Buspirone has a significantly lower discontinuation rate due to adverse events (12.5% vs 20.6%) compared to other augmentation strategies 3, 4, 5
Expecting immediate results from buspirone is a critical pitfall, as it requires 2-4 weeks to reach full therapeutic effect 4, 5
Misdiagnosing autism-related social difficulties as social anxiety disorder leads to inappropriate treatment selection and poor outcomes 1, 2
Failing to consider cognitive therapy is a pitfall, as it has equal efficacy with potentially fewer adverse events and should be offered as an alternative or adjunct 4, 6